All In Biotech

NDA 202317 · Helsinn

Valchlor

Mechlorethamine Hydrochloride · Topical · Alkylating Drug

Orphan

Last checked: Nov 20, 2026Latest source record: May 1, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Aug 23, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

4,887

888 Phase 3, 586 recruiting

FAERS reports

2,247

714 serious, 155 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 20, 2024.

VALCHLOR is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy. VALCHLOR is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy ( 1 ).

Mechanism: Mechlorethamine, also known as nitrogen mustard, is an alkylating agent which inhibits rapidly proliferating cells.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • VALCHLOR · MECHLORETHAMINE HYDROCHLORIDE EQ 0.016% BASE · GEL, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Mechlorethamine" as an intervention, any sponsor and status, largest first.

All 4,887 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pruritus322
  • application site pruritus224
  • application site erythema220
  • application site pain218
  • erythema213
  • condition aggravated194
  • off label use179
  • skin discolouration147
  • rash132
  • skin irritation112
  • blister107
  • death104

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20072
201430
2015256
2016441
2017389
2018253
2019276
2020311
202171
202265
202350
202451
202533
202619

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Valchlor (Mechlorethamine HCl)

2024 spending

$13.9M

Beneficiaries

511

1,821 claims

Per beneficiary

$27,196

$101.41 per unit

View as table
YearSpending
2020$9,143,299
2021$10,322,074
2022$10,955,479
2023$13,320,554
2024$13,897,147

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 147 on PubMed

Sponsor: Helsinn

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.